New Delhi, Apr 18 (PTI) Natco Pharma on Thursday said a complaint has been filed against it at a district court in the US by Fresenius Kabi over the marketing of Diazepam injection prefilled syringe in the country.

Fresenius Kabi USA, LLC and Fresenius Kabi Deutschland GmbH have filed a complaint against Natco Pharma USA LLC (erstwhile Dash Pharmaceuticals LLC) in the District Court of Delaware relating to the marketing of Dash Pharmaceuticals' Diazepam Injection prefilled syringe in the United States, the company said in a regulatory filing.

Also Read | Lok Sabha Elections 2024 Phase 1: When Is Voting and Result? How To Vote, Check Name in Voter List? How To Find Polling Station? Know Everything Here.

Dash Pharmaceuticals LLC had been acquired by Natco Pharma, Inc and had changed its name to Natco Pharma USA LLC.

"Fresenius has not yet effectuated service of the complaint which is required to commence the lawsuit," the filing added.

Also Read | MHADA Maharashtra Lottery 2024: Know Eligibility Criteria, List of Required Documents and How To Apply Online at housing.mhada.gov.in.

Natco Pharma intends to defend the matter accordingly, the company said.

Diazepam injection is indicated in the treatment of anxiety, muscle spasms, and alcohol withdrawal.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)